Navigation Links
Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call
Date:9/8/2011

SUNNYVALE, Calif., Sept. 8, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer and immune mediated diseases, today announced that it will report financial results for the fourth fiscal quarter and fiscal year ended June 30, 2011 after the NASDAQ Market closes on Monday, September 12, 2011.  The company will conduct a conference call and an audio webcast at 4:30 p.m. EDT on the same day. Fiscal Year End Quarter 2011 Conference Call and Webcast DetailsDate: September 12, 2011Time: 4:30 PM EDTListen via Internet: http://ir.pharmacyclics.com/events.cfm Toll-free: +1-877-407-8133International: +1-201-689-8040Replay Number (Toll Free): 877-660-6853  Replay Number (International): 201-612-7415Replay Passcodes (both required for playback):Account #: 286Conference ID #: 378850A webcast replay will be available on the Pharmacyclics website for 30 days.

About PharmacyclicsPharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. We are committed to high
'/>"/>

SOURCE Pharmacyclics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
2. Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings
3. Pharmacyclics to Announce Third Quarter Fiscal 2011 Results and Host a Conference Call on May 4, 2011
4. Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011
5. Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
6. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
7. Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
8. Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
9. Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
10. Pharmacyclics to Present at the RBC Capital Markets Healthcare Investor Conference
11. Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
(Date:1/15/2014)...  In an unprecedented effort to curb the spread of "superbugs" such ... vehicles, an advanced and portable UV germicidal lamp manufactured by MRSA-UV ... In order to prevent EMS paramedics and transport ... West Palm Beach Fire Rescue is the first in ...
(Date:1/15/2014)... 15, 2014  According to Millennium Research Group (MRG), ... the United States and ... will expand moderately through 2022, with embolization particles ... increasing interest in drug-eluting beads (DEBs) and radioembolization ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... Frontage Laboratories, Inc., a ... US and China, and Spaulding Clinical Research, LLC, a ... Medical Device Manufacturer have entered into a strategic partnership ... footprint by combining Frontage,s presence in China and its ...
... SPRING, Md., Sept. 12, 2011 Today, the U.S. ... office responsible for reviewing all drug and biologic applications ... Research,s (CDER) Office of Oncology Drug Products has been ... Products (OHOP). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) ...
Cached Medicine Technology:Spaulding Clinical Announces New Strategic Partnership With Frontage Laboratories, Inc. 2Spaulding Clinical Announces New Strategic Partnership With Frontage Laboratories, Inc. 3FDA Announces Changes in Drug Center's Oncology Office 2FDA Announces Changes in Drug Center's Oncology Office 3
(Date:4/17/2014)... new pain relief targets that could be used ... at King,s College London made the discovery when ... periphery of the body. , Dr Marzia Malcangio ... underlying pain generation and our findings could help ... , One potential side effect of some chemotherapy ...
(Date:4/17/2014)... AURORA, Colo. (April 17, 2014) Two recent ... Medicine researcher and colleagues may help scientists develop ... virus, Yellow fever, Japanese encephalitis and other disease-causing ... of biochemistry and molecular genetics at the School ... the Howard Hughes Medical Institute, and colleagues recently ...
(Date:4/17/2014)... Il. (April 17, 2014) Doctors who treat ... called lymphangioleiomyomatosis (LAM) can face an agonizing treatment ... of the disease and help relieve shortness of ... transplants, and sirolimus can cause potentially fatal complications ... pulmonologist Dr. Daniel Dilling, medical director of Loyola ...
(Date:4/17/2014)... from Boston University School of Medicine (BUSM) have ... consumption in an experimental model. The findings, reported ... Alcohol Abuse , may lead to more effective ... is one of the leading causes of illness ... negative economic impact by limiting the productivity of ...
(Date:4/17/2014)... Council scientists and their partners have found that their ... the transmission of multiple sexually transmitted infections (STIs) in ... simplex virus 2 (HSV-2), and human papillomavirus (HPV). The ... gel is effective against multiple strains of HIV, and ... all three viruses of at least eight hours prior ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... released by glioblastoma cells, can be detected, study shows ... stumbled across a novel mechanism by which brain tumors ... The findings expose a fundamental biological process of which ... be exploited to combat glioblastoma, experts said. But just ...
... nation,s largest and fastest growing database marketing agencies, announced that it ... private, not-for-profit contributor to arthritis research in the world. , ... ... www.merkleinc.com ), one of the nation,s largest and fastest growing database ...
... new website dedicated to tracking the business of robotics. , ... Santa ... is a new website dedicated to tracking the business of robotics. ... this growth industry:, , , , ,   • Service Robots for Governmental and ...
... A new study published in the New England Journal of Medicine ... the detection of heart disease and stroke risk. Life Line ... screenings. , ... Cleveland, OH (PRWeb) November 17, 2008 ...
... Researchers report promising results for the viability of ... technique that may enhance the differential diagnosis of ... skin in vivo. Recently published in "Lasers ... peer-reviewed professional journal of the American Society for ...
... adding the IQAirpurifier to their extensive health product line. For ... ($800 value) with the purchase of one of their Luxury Infrared ... ... 17, 2008 -- EvolutionHealth.com is adding air purifiers to their already ...
Cached Medicine News:Health News:Finding Points to Possible Blood Test for Brain Tumors 2Health News:Finding Points to Possible Blood Test for Brain Tumors 3Health News:Finding Points to Possible Blood Test for Brain Tumors 4Health News:Arthritis Foundation Renews Comprehensive Marketing Contract with Merkle 2Health News:Arthritis Foundation Renews Comprehensive Marketing Contract with Merkle 3Health News:New Website Launched, The Robot Report, Tracking The Business of Robotics 2Health News:New Evidence Found for CRP as an Independent Marker for Heart Disease, Stroke 2Health News:Future Looks Bright For Non-Invasive Diagnosis Of Skin Cancer; Study Shows Novel Light Device Detects Cancerous Lesions From Normal Tissue 2Health News:Future Looks Bright For Non-Invasive Diagnosis Of Skin Cancer; Study Shows Novel Light Device Detects Cancerous Lesions From Normal Tissue 3Health News:EvolutionHealth.com Adds Air Cleansing Purifier to Their Must-Have Products for Health 2Health News:EvolutionHealth.com Adds Air Cleansing Purifier to Their Must-Have Products for Health 3
Adhesive tape sheets for sealing multiwell plates and blocks;...
Microwell Plate Accessories...
DMSO-resistant microplate sealing film...
Amplification Tape 96 featuring 3M adhesive technology. Good optical quality. Minimal autofluorescence. Certified RNase and DNase free....
Medicine Products: